Detail akcie BioInvent Rg online

Business Summary: BioInvent International AB is a Sweden-based biopharmaceutical company, that develops antibody-based drugs for cancer therapies, with two ongoing programs in Phase l/ll clinical trials for the treatment of haematological cancer and solid tumors. The Company’s operational activities are focused on expanding the clinical development of human antibodies, such as BI-1206, BI-1808, BI-1607 and BT-001. The Company has one wholly-owned subsidiary BioInvent Finans AB, which engaged in the administration of warrants issued by the Company.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, BioInvent International AB revenues increased from SEK23.3M to SEK223.5M. Net loss decreased 34% to SEK207.1M. Revenues reflect Revenue from technology licenses segment increase from SEK0K to SEK200.9M, United States segment increase from SEK16.8M to SEK210M, Sweden segment increase from SEK3.4M to SEK12.2M. Basic Earnings per Share excluding Extraordinary Items increased from -SEK4.75 to -SEK3.14.